[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4ec49490e7057072474a18ad9c6dc528ea9194992dc685697e7f09724d3044db",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720740,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 136123727,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4ec49490e7057072474a18ad9c6dc528ea9194992dc685697e7f09724d3044db"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?",
    "summary": "CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.",
    "url": "https://finnhub.io/api/news?id=f433d738414e1574ec5d70cbc8dde3a879c61ce13e4d7ee66fd6a77de2eee946",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753713360,
      "headline": "CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?",
      "id": 136108380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.",
      "url": "https://finnhub.io/api/news?id=f433d738414e1574ec5d70cbc8dde3a879c61ce13e4d7ee66fd6a77de2eee946"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=71cf21e21234cf3bda986be1e260de11d1d45175fd328d278b414e699475b587",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711217,
      "headline": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136108381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=71cf21e21234cf3bda986be1e260de11d1d45175fd328d278b414e699475b587"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "The 3 Things That Matter for Vertex Pharmaceuticals Now",
    "summary": "Some of these developments could improve the company's prospects.",
    "url": "https://finnhub.io/api/news?id=8674698669c7046134df9c64ebbb3b1538b26800340d0706e6620ad40230f63c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753701300,
      "headline": "The 3 Things That Matter for Vertex Pharmaceuticals Now",
      "id": 136108382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Some of these developments could improve the company's prospects.",
      "url": "https://finnhub.io/api/news?id=8674698669c7046134df9c64ebbb3b1538b26800340d0706e6620ad40230f63c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the last six months while the S&P 500 has gained 5.4%.",
    "url": "https://finnhub.io/api/news?id=008835c16aa4073ddfc3dda80f1e01dc8c91c31cd2988d6e719d382772bceca3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753675479,
      "headline": "Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?",
      "id": 136108383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the last six months while the S&P 500 has gained 5.4%.",
      "url": "https://finnhub.io/api/news?id=008835c16aa4073ddfc3dda80f1e01dc8c91c31cd2988d6e719d382772bceca3"
    }
  }
]